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Cancer of the uterine cervix is the third most common cancer 
in women worldwide and the most common cancer among 
Mexican and Latin American women. Risk factors that have 
been associated with the development of cervical intraepi-
thelial neoplasia suggest that Human Papillomavirus (HPV) 
types 16, 18, 31, and 33 entail a high risk of developing 
a malignancy of this type. The accumulation of genetic 
alterations allows the growth of neoplastic cells; chromo-
somal instability is an event that occurs in the precancer-
ous stages. The candidate cancer risk biomarkers include 
cytogenetic endpoints, such as chromo somal aberrations, 
sister chromatid exchange, micronuclei, and the outcomes 
of comet assay and DNA breakage detection-fluorescence 
in situ hybridization. The patterns identified in these cy-
togenetic studies indicate that chromosomal instability is a 
transient and chromosomally unstable intermediate in the 
development of cervical lesions. In this context, the mecha-
nisms that may underlie the progressive increase in genetic 
instability in these patients seem to be related directly to 
HPV infection. The studies discussed in this paper show that 
chromosomal instability may serve as a biomarker by pre-
dicting the progression of cervical intraepithelial neoplasia. 
Nevertheless, these results should be validated in larger, 
prospective studies.
Key words: chromosomal instability, cervical cancer, bio-
marker. 
Introduction. Cancer of the uterine cervix is the third 
most common cancer in women worldwide and the most 
common cancer among Mexican and Latin American 
women [1]. Precancerous lesions of the cervix, com-
monly designated «dysplasia», present a complex problem 
of progression and regression because of their biological 
behavior. Dysplastic lesions of the cervix are morpho-
logically classified into the following stages: mild cervical 
intraepithelial neoplasia (CIN 1), moderate (CIN 2), 
and severe (CIN 3). According to the Bethesda System 
for reporting cervical/vaginal cytological diagnoses [2], 
the lesions are classified as squamous intraepithelial le-
sions (SIL), which are either low-grade (LG-SIL), corre-
sponding to human papillomavirus (HPV) infection and 
CIN 1, or high-grade (HG-SIL), corresponding to CIN 
2 and CIN 3. Risk factors that have been associated with 
the development of CIN suggest that HPV types 16, 18, 
31, and 33 entail a high risk of developing a malignancy 
of this type.
Considering that carcinogenesis is a complex stepwise 
process and that the accumulation of genetic alterations 
allows the growth of neoplastic cells, chromosomal insta-
bility is an event that occurs in the precancerous stages.
The development and validation of biomarkers that 
can anticipate the clinical diagnosis and suggest cancer 
prevention interventions in populations at risk are among 
the most promising strategies for cancer prevention. The 
candidate cancer risk biomarkers include cytogenetic 
endpoints, such as chromosomal aberrations [3], sister 
chromatid exchange (SCE) [4], micronuclei (MN) [5], 
and the outcomes of comet assay [6, 7] and DNA break-
age detection-fluorescence in situ hybridization (DBD-
FISH) [8].
Chromosomal aberrations. Numerical changes in spe-
cific chromosomes (aneusomy) can involve a gain (e.g., 
trisomy) or loss (e.g., monosomy) with respect to the 
normal condition (disomy). A misdivision gives rise to 
an amplification of the whole genome (polyploidy) [9] 
and structural anomalies (e.g., deletions, translocations, 
and isochromosomes).
Numerical or structural chromosomal anomalies, or 
a combination of the two, are related events that oc-
cur during the early stages and progression of cervical 
carcinogenesis [10, 11]. The numerical and/or structural 
deviations of some chromosomes (i.e., monosomy and 
polysomy of chromosomes 1, 3, and X) are routinely 
used as positive genetic biomarkers in the diagnosis of 
cervical cancer and prediction of disease progression 
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[12–14]. Structural anomalies and numerical anoma-
lies (aneusomy) of chromosome 1 have been described 
as the most frequent karyotypic changes in cervical 
cancer. It is possible that one or more of the tumor 
suppressor genes (PAX7, FBG3, ARH1, NEK2, RGL, 
and ARCH) located on chromosome 1 are involved 
in the development or progression of cervical cancer 
[15]. Aneusomy in chromosomes 1, 7, 8, 11, 17, and X 
have also been reported based on fluorescence in situ 
hybridization (FISH) and interphase cytogenetic find-
ings [16–21]. In addition to the primary structural and 
numerical aberrations that are responsible for the initia-
tion of carcinogenesis, new or secondary chromosomal 
abnormalities in the karyotype (e.g., stickiness, pulveri-
zation, chromatin extraction, chromatid gap, chromatid 
constriction, isochromatid break, endomitosis, and ring 
chromosomes) of a patient may appear as signaling a 
change usually to a more aggressive disorder [22]. An 
increased frequency of spontaneous chromosome aber-
rations was observed among patients with cervical pre-
cancerous lesions [23].
Sister chromatid exchange (SCE) is a reciprocal ex-
change between sister chromatids. SCEs are generally 
visualized by exposing cells (in vitro or in vivo) to 5-bro-
modeoxyuridine for two cell cycles and allowing subse-
quent differential staining of sister chromatids. Exchanges 
are detected at switches in stained regions between sister 
chromatids. The molecular mechanisms underlying SCE 
are not known fully, but they occur after exposure to vari-
ous genotoxic agents and are believed to indicate DNA 
damage [24]. The SCE phenomenon is widely used as a 
reliable indicator of chromosome (DNA) instability [25] 
and has been suggested as a preclinical marker for the 
breast cancer gene [26].
The performance of the SCE test to evaluate the 
genomic damage in patients with cervical carcinoma 
is more practical in cultured lymphocytes than in solid 
tumors because of the difficulties in obtaining surgical 
specimens. The use of lymphocytes is based on the as-
sumption that there should be an association between the 
extent of chromosomal damage in lymphocytes and in 
tumor cells [27]. A significant increase of the number of 
SCEs was reported previously in patients with cancer of 
the uterine cervix [28–33]; however, other studies have 
not shown significant differences [34]. These results sug-
gest that the frequency of SCE is higher in patients with 
cervical carcinoma than in controls, in studies with a 
statistical power of 0.80. It could be assumed that these 
patients show a certain amount of chromosome instabil-
ity. This finding is in agreement with those reported by 
other authors [27–33]. High values of statistical power 
(0.99 to 1.00) were achieved in all references listed in Ta-
ble I (computed by the authors using the Stata software) 
[34]. Conversely, Adhvaryu et al. [35] did not find that 
SCE was a significant marker in cervical cancer patients, 
possibly because of the low statistical power (1 – ȕ = 
= 0.57) in the experimental design.
SCEs are associated with cervical cancer. The incon-
sistency of the results of other studies might be attribut-
able to the low statistical power in the experimental de-
sign of those studies; however, the usefulness of increased 
SCE levels as a preclinical marker to identify women at 
a high risk of developing cancer needs to be ascertained 
in follow-up studies of precancerous lesions with high 
levels of SCE.
Micronuclei. A micronucleus (MN) is formed by 
chromosomes or chromosome segments that fail to be in-
corporated in the nuclei during cell division. MN can be 
generated through various processes, i.e., chromosomal 
damage and chromosome loss (aneuploidy). During the 
past few decades, MN has generally been used as a bio-
marker of chromosomal damage, genome instability, and 
cancer risk, integrating acquired mutations and genetic 
susceptibility toward mutations [36]. Therefore, increased 
MN frequency is expected in preneoplastic conditions, 
which has been demonstrated [37–41]. The role of MN 
in various steps of carcinogenesis has been substantiated 
by investigators and it has clearly been shown that the 
level of baseline chromosome damage is much higher in 
untreated cancer patients than in cancer-free controls 
[42]. Therefore, MN scoring could be used as a biomarker 
to identify various preneoplastic conditions much earlier 
Table 1. Sister chromatid exchange frequencies 
in women with carcinoma of the uterine cervix 
in studies with various statistical powers [34]
Indications. N – number of patients studied; P < 0.05;
C – control, P – patients, X ± SD – average ± standard 
deviation.
Author N
SCE 
(X ± SD)
Statis-
tical
power
Mitra et al. [28] 
Murty et al. [29] 
Adhvaryu et al. 
[35] 
Yokota et al. 
[32] 
Lukovic et al. 
[30]
Dhillon et al. 
[31]
Capalash et al. 
[33]
Cortés-Gutiérrez 
et al. [34]
13 
11
46
43
13 
13 
35
18 
21
19 
14 
20
30
15
28
28
10.05 ± 2.35 (C)*
6.95 ± 1.53 (P)
10.15 ± 2.49 (C)*
7.55 ± 2.24 (P)
9.68 ± 0.97 (C)
8.91 ± 1.15 (P)
10.00 ± 1.80 (C)*
7.60 ± 0.80 (P)
8.92 ± 1.47 (C)*
6.94 ± 1.00 (P)
9.44 ± 1.27 (C)*
6.09 ± 1.07 (P)
7.18 ± 1.23 (C)*
4.68 ± 1.82 (P)
7.80 ± 1.05 (C)*
6.98 ± 1.13 (P)
0.99
1.00
0.57
1.00
 0.99
 1.00
1.00
0.80
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than the manifestations of clinical features and might 
specifically be exploited in the screening of high-risk 
populations for a specific type of cancer [43, 44]. For 
these reasons, the prevalence of MN in epithelial cells 
has been considered a potential tissue-specific indicator 
of cancer risk [43, 44]. Occasional studies have shown 
increased MN frequency in invasive cervical cancer and 
researchers have suggested that the MN score in exfo-
liated cervical cells may be an additional criterion for 
establishing cervical cancer risk [37, 45]. However, there 
are only a limited number of studies on MN scoring 
for the assessment of cervical cancer risk [37, 45] and 
on MN scoring in cervical preneoplastic and neoplastic 
conditions [11, 46]. Accordingly, an analysis of MN in 
Table 2. Micronuclei frequencies in women with cervical neoplasic lesions as reported in the literature
Author N Diagnostic
No. cells 
studied
MN Conclusion
Samanta et al. 
[55] 
Samanta et al. 
[54] 
Aires et al. 
[53]  
Campos et al. 
[52]   
Leal-Garza et 
al. [47] 
Cerqueira et 
al. [51] 
Chakrabarti et 
al. [50] 
30
23
40
40
30
38
22
10 
12 
10 
27 
35
10
25
16
15
10
10
10
10
45
113
24
14
4
48
33
32
6
ASCUS
CIN
Control
Inflammatory
ASC-US
LG-SIL
HG-SIL
Control
Inflammatory
LG-SIL
HG-SIL
Control
Inflammatory
CIN 1
CIN 2
CIN 3
Control
LG-SIL
HG-SIL
Invasive
Control
Inflammatory 
LG-SIL
HG-SIL
Cancer
Control
Inflammatory
LG-SIL
HG-SIL
30,000
23,000
40,000
40,000
30,000
38,000
20,000
24,000
20,000
54.000
35,000
10,000
25,000
16,000
15,000
10,000
10,000
10,000
10,000
145,388
345,235
65,171
43,086
10589
24,000
16,500
16,00
300
2.87 ± 2.21* 
8.35 ± 6.45
1.05 ± 1.59*
0.42 ± 0.71
2.87 ± 2.21
4.74 ± 5.62
19.73 ± 17.18
3**
7
8
61
1.3 ± 1.4*
7.2 ± 9.6
4.3 ± 4.3
10.6 ± 5.3
22.7 ± 11.9
3.05*
7.1
9.7
14.0
27**
166
38
47
14
1.91**
3.80
3.5 
4.0
MN score may be helpful in identifying the 
true CIN cases that are mislabeled as ASCUS 
on cervical smear. In future, MN score can 
be used as an additional biomarker in cervical 
cancer screening 
MN scoring on the epithelial cells of cervix 
could be used as a biomarker in cancer scre-
ening. This is an easy, simple, reliable, repro-
ducible and objective test and can be done on 
routinely stained smears
MN test and Papanicolaou test may be both 
utilized for screening women who are at risk 
of developing cervical cancer 
The prevalence of MN in exfoliated uterine 
cervical cells was greater in the patients with 
one or more risk factors for cancer than in the
patients without risk factors
A positive linear trend between the MN fre-
quency and increased cervical cancer risk. 
After being validated, MN could be used as 
screening and annual PAP test and as part of 
cancer staging 
MN testing would be helpful in monitoring 
smokers with cervical intraepithelial lesions 
The rising frequency of MN in exfoliated ce-
rvical cells reflects a sustained mutagenesis in 
cervical epithelium
Indications. N – number of cells studied; ASCUS – Atypical Cells of Undetermined Significance; CIN – Cervical 
Intraepithelial Neoplasia; LG-SIL – low-grade squamous intraepithelial lesion; HG-SIL – high-grade squamous 
intraepithelial lesion. * Frequencies of MN/1000 cells. ** Frequencies of MN/100 cells.
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peripheral blood lymphocytes (PBLs) revealed the pres-
ence of a correlation between MN frequency and grade 
of cervical lesions [47] and provided evidence that MN 
frequency in PBLs is a predictive biomarker of cancer risk 
within a population of healthy subjects [48].
The similarity between the level of chromosome dam-
age in surrogate tissues, such as oral mucosa or PBLs, 
and the corresponding damage in cancer-prone tissues 
provided the rationale for the use of these biomarkers as 
markers of cancer risk [49].
Several studies reported an association between MN 
frequency and progression of precursor lesions of cervi-
cal cancer [46, 47, 50–54]; however, the elevation in 
the number of these structures in women with HG-SIL 
did not reach significance. Samanta et al. [55] reported a 
significant increase of MN in CIN lesions compared with 
Atypical Cells of Undetermined Significance (Table 2).
A recent study [56] provided strong evidence that MN 
frequency assessed in the PBLs of disease-free subjects 
is a good predictor of cancer death risk, as evaluated in 
a nested case-control study performed 14 years after the 
original recruitment.
In particular, the high reliability and low cost of the 
micronucleus assay has contributed to the worldwide suc-
cess and adoption of this biomarker for in vitro and in 
vivo studies of genome damage in cervical neoplasia [57].
Comet assay. The comet or single-cell gel electropho-
resis (SCGE) assay is now widely accepted as a standard 
method for the assessment of DNA damage in individual 
cells. It has been used in a wide variety of applications, 
including human biomonitoring, genotoxicology, and 
ecological monitoring, and as a tool to investigate DNA 
damage and repair in various cell types. It can be used to 
detect the DNA damage in individual cells and to assess 
the presence of double-stranded breaks, single-stranded 
breaks, and alkali-labile sites [6].The sensitivity of the 
SCGE assay and its ability to measure DNA damage in 
individual cells have rendered it a rapid tool that is use-
ful in addressing a wide range of questions in biology, 
medicine, and genetic toxicology.
Several studies have shown that basal DNA damage 
is increased in PBLs of patients suffering from a variety 
of cancers, including head and neck, breast, renal, es-
ophageal, bladder, ovarian, and lung cancer. The authors 
of many of these studies, as well as other studies, have 
also extracted PBLs from cancer patients (usually prior 
to radiotherapy or chemotherapy) and exposed them to 
DNA-damaging agents in vitro, to assess whether the 
susceptibility to DNA damage and subsequent repair ca-
pacity in these cells are significantly different from those 
observed in control samples [6].
A direct association between genomic damage in cer-
vical epithelial cells and the progression of LG-SIL to 
HG-SIL has been demonstrated in two studies [58, 59]. 
The SCGE assay may serve as a novel tool to predict the 
fate of cervical dysplasia; however, further standardiza-
tion and experimental validation studies are needed.
DNA breakage detection-fluorescence in situ hybridi-
zation (DBD-FISH). This technique is a new procedure 
that allows the cell-by-cell detection and quantification 
of DNA breakage in the whole genome or within spe-
cific DNA sequences. Cells embedded in an inert agarose 
matrix on a slide are lysed to remove membranes and 
proteins and the remaining nucleoids are subjected to 
controlled denaturation with an alkali. The alkali trans-
forms DNA breaks into restricted single-stranded DNA 
(ssDNA) motifs, which can be detected via hybridization 
with specific or whole-genome fluorescent DNA probes. 
As the number of DNA breaks increases in a target region, 
so do the amounts of ssDNA produced and probes hy-
bridized, resulting in a more intense FISH signal, which 
can be quantified using image analysis systems [60–62]. 
Moreover, the alkaline treatment may break the sugar-
phosphate backbone at basic sites or at sites with deoxyri-
bose damage, transforming these lesions into DNA breaks 
that are also converted into ssDNA. DNA damage levels 
may be a consequence of the torsional stress on DNA 
loops associated with tight chromatin packing, may vary 
among cell types in conventionally conformed genomes 
(e.g., sperm and lymphocytes) [63], and may change if 
the cell is under stress, such as in the presence of a viral 
infection.
DNA damage is a product of external stressors, which 
also act on the genome [64]. It may also be a consequence 
of the torsional stress on DNA loops that is associated 
with tight chromatin packing. Abundant damage has been 
found in the chromatin of condensed mitotic chromo-
somes [64]. In addition, the exposure of DNA to con-
stant tension above a critical level leads to its unwinding 
[65]. Although the molecular biology and significance of 
constitutive DNA damage are not well understood, some 
observations support the idea that these genomic regions 
escape the normal DNA configuration and may be tran-
sient structural features of cells. Even under homeostatic 
cell conditions, the presence of DNA breakage may vary 
among cell types [63]. It is noteworthy that the applica-
Table 3. Comparison of the integrated density (ID) after 
fluorescence densitometry, in cervical epithelial cells 
of control women, women with LG-SIL, and women 
with HG-SIL, as assessed using DBD–FISH [70]
Indications. N – number of cells studied; ID – fluo-
rescence area × fluorescence intensity; a Different to cont-
rol (p = 0.0001); b Different to LG-SIL (p = 0001); 
c Different to HG-SIL (p = 0.0001).
Group N
Number of 
studied cells
ID (X ± SD)
Control
LG-SIL 
HG-SIL
10
10
10
500
500
500
38 E7 ± 70 E7 b,c
926 E7 ± 1926 E7 a,c
4339 E7 ± 3161 E7 a,b
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tion of a whole-genome probe to other somatic cells does 
not yield a homogeneous background DBD-FISH signal, 
as certain chromatin regions are more strongly labeled. In 
human leukocytes, the DBD-FISH areas with a more in-
tense background visualized using a whole-genome probe 
corresponded to areas containing 5 bp satellite DNA 
sequences [66]. In mouse splenocytes, the background 
areas corresponded to repetitive DNA satellite sequences 
located in pericentromeric regions [67], whereas in Chi-
nese hamster cells, they corresponded to pericentromeric 
interstitial telomeric-like DNA sequences [68]. Their 
presence is not limited to mammalian species, as they 
have also been found in insects [69].
Cortés-Gutiérrez et al. [70] reported that LG-SIL 
patients exhibited a hybridization signal that was 20 times 
greater than the signal observed in control individuals, 
which reflected the basal level of DNA damage detected, 
and that HG-SIL patients exhibited a hybridization signal 
that was 100 times greater than the basal control signal 
(Table 3).
The DBD-FISH technique is easily applicable to cer-
vical scrapings and provides prompt results that are easy 
to interpret; however, these results need to be validated 
in larger prospective studies.
Genomic instability in cervical cancer. The possible 
mechanisms that may explain the progressive increase of 
DNA damage in patients with cervical neoplasia include: 
1) metabolic stress due to tumor growth; 2) a «clasto-
genic» product released by tumor cells; 3) micronutrient 
deficiencies, such as folate and vitamin B12 deficiencies 
[71, 72], and HPV infection. HPV DNA can be detected 
in 95–100 % of cervical cancer specimens and it has been 
called a «necessary cause» of cervical cancer [4, 73]. Alva-
rez-Rosero et al. [74] observed a correlation between the 
presence of high-risk HPV infection in cervical cells and 
the induction of genomic instability (chromosomal aber-
rations) in lymphocytes.  Similarly, Cortés-Gutiérrez et al. 
[75] reported that women with HPV infection had a higher 
MN frequency in cervical cells. A chromosomal profile of 
high-grade cervical intraepithelial neoplasia was related to 
duration of preceding high-risk HPV infection [76].
Mechanistically, chromosome breakage in HPV-on-
coprotein-expressing cells probably increases the cellular 
susceptibility to DNA damage or the defective repair 
Table 4. Classic cytogenetic tests as candidate biomarkers of cervical cancer risk
Cytogenetic 
test
Sample (tissue) Advantages Limitations Validations
Chromosomal
abnormalities
SCE
MN 
Comet assay
Lymphocytes
Lymphocytes 
Lymphocytes 
Cervical epithelium
Lymphocytes 
Cervical epithelium 
Indicator chromosomal in-
stability
Sensible indicator chromo-
somal instability
Easy, simple, reliable, repro-
ducible, objective, and low
cost 
No required cellular culture
Easy, simple, reliable, repro-
ducible, objective, and low 
cost 
Sensitive, rapid and versatile
 
Sensitive, rapid and versatile.
No required cellular culture
Required cellular cul-
ture
Laborious results in-
terpretation
Required cellular cul-
ture
Laborious results in-
terpretation
Required cellular cul-
ture 
Limited number of stu-
dies in cervical pre-
neoplastic lesions [11, 
37, 45, 46]
Required fluorescence 
equipment.
Few studied in dys-
plasias [58, 59]
Inconsistency of the re-
sults [10–23]
The inconsistency of the 
results [28–34]
Strong evidence of good 
predictor of cancer death
risk [56]
Taking into account the
role of possible confoun-
ders and effect modifiers
Consistency of results
Validation and detailed 
follow up studies are re-
quired
Experimental validation, 
standardization and in-
terpretation are needed
Validation and detailed 
follow up studies are re-
quired
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of DNA damage as a consequence of reduced p53 or 
pRB function [77]. The HPV-16 E7 oncoprotein induces 
centrosome abnormalities, thereby disrupting mitotic fi-
delity and increasing the risk for chromosome misseg-
regation and aneuploidy. In addition, expression of the 
high-risk HPV E7 oncoprotein stimulates DNA replica-
tion stress, which is a potential source of DNA breakage 
and structural chromosomal instability [78, 79]. Unre-
paired, broken DNA can promote gene translocations 
or gene amplifications/deletions, which may provide a 
growth advantage to cells through gain of oncogenes or 
loss of tumor suppressors. This chromosomal instability 
may promote the development of cells with numerical 
and structural aberrations in chromosomes 1, 3, 5, 11, 
and 17 [12, 74, 80], which are critical factor for cervi-
cal carcinoma development and malignant progression 
[12, 13].
Several lines of evidence show that expression of 
HPV-16 E6 and E7 can independently induce structural 
chromosomal instability using the comet assay [77].
The induction of chromosomal instability is an emer-
ging topic in viral tumorigenesis in humans and is as-
sociated with high-risk HPV [81], hepatitis B virus [82], 
Kaposi’s sarcoma herpesvirus [83], and human T-cell 
leukemia virus type 1 (HTLV-1) [84]. The level of DNA 
damage in the genome as a structural feature of the chro-
matin may be unbalanced after exposure of cells to stress, 
such as a viral infection. Several studies have reported 
changes in chromatin organization during carcinogen-
esis and the subsequent association of distorted DNA-
binding proteins with the nuclear matrix, which may have 
a functional role in chromatin organization and gene 
regulation [85]. An increase in the incidence of DNA 
single breakage (dsb), which is mediated by Ku70 deple-
tion, is associated with HPV-16 episomal loss in cervical 
keratinocytes and with a new integration event. Normal 
levels of host DNA repair proteins, including Ku70, may 
protect against such events by preventing the genera-
tion of host dsb and linearized viruses. Interestingly, the 
HPV-16 E7 protein may play a direct role in inducing 
integration by interference with the nonhomologous end 
joining (NHEJ) pathway. Expression of HPV-16 E7 in 
the HPV-negative cervical keratinocyte cell line C33A 
resulted in the upregulation of the Ku70-binding pro-
tein [86], which may interfere with normal NHEJ and 
increase the frequency of dsb. Despite the well known 
function of HPV-16 E7 to induce DNA damage, the 
precise source of DNA double strand breaks remains 
poorly understood.
Clinical significance. From a clinical perspective, the 
presence of chromosomal instability may help distinguish 
patients with clinically significant cervical lesions from 
those who have insignificant lesions, thus discriminating 
lesions (Table 4). The ease and low cost of the detection 
of MN may allow its use as a prognostic indicator dur-
ing the planning and validation of programs for cancer 
monitoring and prevention. In brief, MN scoring on the 
epithelial cells of the cervix could be used as a biomarker 
in cancer screening. This is an easy, simple, reliable, re-
producible, and objective test that can be performed on 
routine stained smears. 
Further investigations are required to confirm and 
validate the results of chromosomal abnormalities, SCE, 
and comet assay. Moreover, the results of DBD-FISH 
are preliminary.
Conclusions and future directions. Cervical cancer is 
the corollary of a long process that has its onset in LG-
SIL and HG-SIL precursor lesions. Vaccination against 
HPV infection and periodical Papanicolaou cervical cy-
tological screening are effective measures for preventing 
cervical cancer. Despite the effectiveness of Papanicolaou 
examinations, the detection of chromosomal instability 
as an early biomarker of cervical cancer risk should be 
improved, to reduce the incidence of cervical cancer. Ad-
ditional research is needed, not only to gain better insight 
into the association between the frequency of MN and 
cancer, but also to evaluate the benefits of including bio-
markers of cancer risk in the surveillance of populations 
at increased environmental or genetic risk. The former 
goal is easier to achieve, and plans already exist within 
the framework of the HUMN project for increasing the 
size of the study group, both by including new national 
cohorts and by extending the length of the follow-up 
period for those cohorts currently included in the study. 
The latter goal implies an improved understanding of the 
association between chromosome instability and cervical 
cancer. In particular, the consideration of the role of 
possible confounders and effect modifiers, such as diet, 
oxidative stress, and genetic polymorphisms, would be 
desirable before the routine application of these biomark-
ers in population studies aimed at estimating the risk of 
cancer.
E.I. Cortés-Gutiérrez, M.I. Dávila-Rodríguez, 
R.M. Cerda-Flores
ÕÐÎÌÎÑÎÌÍÛÅ ÏÎÂÐÅÆÄÅÍÈß 
ÊÀÊ ÏÐÎÃÍÎÇÍÛÅ ÌÀÐÊÅÐÛ 
ÊÀÐÖÅÍÎÃÅÍÅÇÀ ØÅÉÊÈ ÌÀÒÊÈ
Ðàê øåéêè ìàòêè ÿâëÿåòñÿ òðåòüèì ïî ðàñïðîñò-
ðàíåííîñòè â ìèðå òèïîâ ðàêà ó æåíùèí è íàè-
áîëåå ÷àñòî âñòðå÷àþùèìñÿ ó æåíùèí Ìåêñèêè è 
Ëàòèíñêîé Àìåðèêè. Ôàêòîðû ðèñêà, ñâÿçàííûå ñ 
ðàçâèòèåì èíòðàýïèòåëèàëüíîé öåðâèêàëüíîé íåî-
ïëàçèè, ïðåäïîëàãàþò, ÷òî ïàïèëëîìàâèðóñ ÷åëîâåêà 
(HPV) òèïîâ 16, 18, 31 è 33 âëå÷åò çà ñîáîé âûñîêèé 
ðèñê ðàçâèòèÿ îïóõîëåé ýòîãî òèïà. Íàêîïëåíèå ãå-
íåòè÷åñêèõ èçìåíåíèé äåëàåò âîçìîæíûì ðîñò îïó-
õîëåâûõ êëåòîê; õðîìîñîìíàÿ íåñòàáèëüíîñòü ÿâ-
ëÿåòñÿ ñîáûòèåì, êîòîðîå ïðåäøåñòâóåò ïðåäðàêî-
âûì ñòàäèÿì. Âîçìîæíûå áèîìàðêåðû ðèñêà îïóõî-
ëè âêëþ÷àþò öèòîãåíåòè÷åñêèå êðèòåðèè, òàêèå êàê
õðîìîñîìíûå àáåððàöèè, îáìåí ñåñòðèíñêèõ õðîìà-
òèä, ìèêðîÿäðà, è çàêàí÷èâàþòñÿ Comet-àíàëèçîì è 
ISSN 0564–3783. Öèòîëîãèÿ è ãåíåòèêà. 2014. Ò. 48. ¹ 360
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äåòåêöèåé ïîëîìîê ÄÍÊ ñ ïîìîùüþ ôëþîðåñöåíò-
íîé ãèáðèäèçàöèè in situ. Îáðàçöû, èäåíòèôèöèðî-
âàííûå â òàêèõ öèòîãåíåòè÷åñêèõ èññëåäîâàíèÿõ, ïî-
êàçûâàþò, ÷òî õðîìîñîìíàÿ íåñòàáèëüíîñòü ÿâëÿåòñÿ 
òðàíçèåíòíûì ïðîìåæóòî÷íûì çâåíîì â ðàçâèòèè 
öåðâèêàëüíûõ íàðóøåíèé. Â ýòîé ñâÿçè ìåõàíèçìû, 
êîòîðûå ìîãóò ëåæàòü â îñíîâå ïðîãðåññèðóþùåé 
ãåíåòè÷åñêîé íåñòàáèëüíîñòè ó òàêèõ ïàöèåíòîâ, êà-
æóòñÿ íåïîñðåäñòâåííî ñâÿçàííûìè ñ èíôåêöèåé 
HPV. Íàñòîÿùåå èññëåäîâàíèå ïîêàçûâàåò, ÷òî õðî-
ìîñîìíàÿ íåñòàáèëüíîñòü ìîæåò ñëóæèòü áèîìàð-
êåðîì äëÿ ïðåäñêàçàíèÿ ðàçâèòèÿ èíòðàýïèòåëè-
àëüíîé öåðâèêàëüíîé íåîïëàçèè, òåì íå ìåíåå ýòè
ðåçóëüòàòû äîëæíû áûòü îöåíåíû â áîëåå ìàñøòàá-
íûõ èññëåäîâàíèÿõ.
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